{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"<div>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma</div>","eudractNumber":"2020-000562-41","id":7242,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04989803","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-01-01T08:43:59+01:00","shortTitle":"KT-US-499-0150","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</div>","eudractNumber":"2020-005843-21","id":7303,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05041309","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-02-16T13:40:47+01:00","shortTitle":"KT-US-982-5968","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, \nPHARMACOKINETICS AND PHARMACODYNAMICS OF KUP-101A \nIN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS","eudractNumber":"2025-522402-21","id":11935,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau3","name":"Spinaliom (Plattenepithelkarzinom)"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03416335","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-01T13:01:11+02:00","shortTitle":"KUP-CT01","therapeutical":true,"therapyLines":[{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)<br />","eudractNumber":null,"id":370,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2011-09-23T09:28:47+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"AML-Register und Biomaterialdatenbank der Studienallianz Leuk&#228;mie (SAL) und der AML Cooperative Group (AML-CG)","eudractNumber":null,"id":5759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2019-04-29T09:32:46+02:00","shortTitle":"Klinisches AML-Register (SAL, AML-CG)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Analyse des Gesamt- und Tumorfreien &#220;berlebens von Patienten mit Kolonkarzinomen als indirekter Parameter der Chemotherapie-Effektivit&#228;t einer definierten Chemotherapie in Abh&#228;ngigkeit von der anatomischen Lokalisation des Prim&#228;rtumors im adjuvanten Ansatz.","eudractNumber":null,"id":8311,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T08:18:06+02:00","shortTitle":"Kolonsegment(Chemo)-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Molekulares Fingerprinting zur Krebserkennung<div><br /></div><div>DRKS00019844</div>","eudractNumber":null,"id":11557,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-06-15T12:24:56+02:00","shortTitle":"L4L","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Register low-grade muzin&#246;se\nNeoplasien der Appendix (LAMN)<div><br /></div>","eudractNumber":null,"id":8732,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-04-14T09:42:07+02:00","shortTitle":"LAMN-Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with with primary high-risk lobular breast cancer - LOBSTER","eudractNumber":"2023-509292-17-00","id":9924,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06607757","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-11T13:29:47+01:00","shortTitle":"LOBSTER","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"Data collection to design and validate LEOPARD predictive models of delisting in liver transplant candidates","eudractNumber":null,"id":11696,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06675604","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2026-03-01T12:08:50+01:00","shortTitle":"Leopard","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}